+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 99Years
All Genders
ID07566195

A Phase III Extension Study Evaluating Long-Term Safety of Two Tozorakimab Dose Regimens in Adults with Chronic Obstructive Pulmonary Disease and History of Exacerbations

Led by AstraZeneca · Updated on 2026-10-16

59

Participants Needed

13

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the long-term safety of two different dose regimens of tozorakimab in adults with chronic obstructive pulmonary disease COPD who have a history of exacerbations. It is a Phase III, open-label, multicenter extension study including participants who have completed earlier related studies. The study is designed to assess how well participants tolerate the medication over an extended period. Participants receive subcutaneous injections of tozorakimab through pre-filled syringes, following one of two dose regimens based on their prior study participation. The study monitors these treatments chronically, lasting up to several years, to observe safety outcomes. This extension study allows continued dosing and long-term evaluation. During the study, participants will be regularly assessed for adverse events over 2 to 3 years. Researchers will monitor safety through ongoing clinical evaluations and collect data on any side effects experienced. Participants must consent and continue contraceptive use as agreed in previous studies. The study ensures close observation to understand the long-term impact of tozorakimab in managing COPD exacerbations.

CONDITIONS

Brief Title

Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here